Molly R. Sherwood
Research Subjects
Molly R. Sherwood has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Philip C. Spinella
Trauma and Transfusion Medicine Research Center, Department of Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
4 shared publications - Christine M. Leeper
Trauma and Transfusion Medicine Research Center, Department of Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
3 shared publications - Marion E. Granger
University of South Carolina, Columbia, South Carolina
3 shared publications - Mark H. Yazer
Department of Clinical Immunology Odense University Hospital Odense Denmark
3 shared publications John B. Holcomb
Department of Surgery University of Alabama Birmingham Alabama USA
2 shared publications- Kenneth Joseph Moise
Dell Medical School, The University of Texas at Austin, Austin, Texas
2 shared publications
Latest Publications
- 1 September 2026
- Published by Taylor & Francis in Prehospital Emergency Care
- p. 1-12
RhD-Positive Transfusion in Females of Childbearing Potential in Hemorrhagic Shock: Risk, Reality, and Policy
Prehospital transfusion using Rhesus D antigen (RhD)-positive low-titer group O whole blood (LTOWB) or red blood cells is increasingly common when RhD-negative blood products are not available. However, concerns remain regarding D-alloimmunization in RhD-negative females of childbearing potential (FCPs), which could lead to future hemolytic disease of the fetus and newborn (HDFN). The magnitude of these risks, and their policy implications, have been the subject of recent investigation. To summarize the biological and epidemiological impacts and post-exposure management of RhD-positive transfusion in FCPs in hemorrhagic shock. This narrative review synthesizes the literature on the rate of D-alloimmunization, describes the results of modeling studies on the risk of HDFN following RhD-positive transfusion to FCPs, and examines epidemiologic studies estimating the HDFN risk at local, regional, and national levels. The D-alloimmunization risk mitigation strategies and current clinical guidelines are also reviewed. Several factors, including the low prevalence of RhD-negative individuals, the low rate of D-alloimmunization itself, potentially reduced pregnancy rates post-trauma, and advances in modern perinatal care decrease the overall risk of HDFN following the transfusion of RhD-positive blood products to FCPs in trauma. Some modeling studies estimated that fetal death due to anti-D-mediated HDFN would occur in fewer than 0.1% of FCPs exposed to RhD-positive blood products. Timely prehospital transfusion has demonstrated survival benefits for injured adults and children. National and regional epidemiological studies support the safety and utility of RhD-positive blood product use in emergency settings. Risk mitigation strategies include Rh immune globulin (RhIg) administration and structured post-exposure follow-up to detect alloimmunization and reduce potential future pregnancy harm. RhD-positive transfusion in FCPs during hemorrhagic shock when RhD-negative products are not available is supported by current evidence and ethical considerations. The risk of future HDFN is low and favorable perinatal outcomes can be achieved when the woman has access to modern prenatal health care. Risk may be further mitigated through post-exposure protocols. Prehospital transfusion policies should reflect this risk-benefit balance by enabling access to RhD-positive blood products for all trauma patients, including FCPs, if RhD-negative blood products are not available.
- 1 September 2026
- Published by Taylor & Francis in Prehospital Emergency Care
- p. 1-12
RhD-Positive Transfusion in Females of Childbearing Potential in Hemorrhagic Shock: Risk, Reality, and Policy
Prehospital transfusion using Rhesus D antigen (RhD)-positive low-titer group O whole blood (LTOWB) or red blood cells is increasingly common when RhD-negative blood products are not available. However, concerns remain regarding D-alloimmunization in RhD-negative females of childbearing potential (FCPs), which could lead to future hemolytic disease of the fetus and newborn (HDFN). The magnitude of these risks, and their policy implications, have been the subject of recent investigation. To summarize the biological and epidemiological impacts and post-exposure management of RhD-positive transfusion in FCPs in hemorrhagic shock. This narrative review synthesizes the literature on the rate of D-alloimmunization, describes the results of modeling studies on the risk of HDFN following RhD-positive transfusion to FCPs, and examines epidemiologic studies estimating the HDFN risk at local, regional, and national levels. The D-alloimmunization risk mitigation strategies and current clinical guidelines are also reviewed. Several factors, including the low prevalence of RhD-negative individuals, the low rate of D-alloimmunization itself, potentially reduced pregnancy rates post-trauma, and advances in modern perinatal care decrease the overall risk of HDFN following the transfusion of RhD-positive blood products to FCPs in trauma. Some modeling studies estimated that fetal death due to anti-D-mediated HDFN would occur in fewer than 0.1% of FCPs exposed to RhD-positive blood products. Timely prehospital transfusion has demonstrated survival benefits for injured adults and children. National and regional epidemiological studies support the safety and utility of RhD-positive blood product use in emergency settings. Risk mitigation strategies include Rh immune globulin (RhIg) administration and structured post-exposure follow-up to detect alloimmunization and reduce potential future pregnancy harm. RhD-positive transfusion in FCPs during hemorrhagic shock when RhD-negative products are not available is supported by current evidence and ethical considerations. The risk of future HDFN is low and favorable perinatal outcomes can be achieved when the woman has access to modern prenatal health care. Risk may be further mitigated through post-exposure protocols. Prehospital transfusion policies should reflect this risk-benefit balance by enabling access to RhD-positive blood products for all trauma patients, including FCPs, if RhD-negative blood products are not available.
- Open Access
- 31 July 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 16 (03) , e171-e178
Understanding Patient Perspectives and Experiences in Severe Hemolytic Disease of the Fetus and Newborn: Insights from Qualitative Interviews
Objective Maternal red cell alloimmunization is a rare pregnancy condition that can cause hemolytic disease of the fetus and newborn (HDFN), which can be serious and fatal. As subsequent alloimmunized pregnancies carry HDFN risk, families’ future pregnancy decisions may be affected. Findings from qualitative interviews in alloimmunized mothers are presented to understand experiences and perspectives during their previous pregnancy affected by severe HDFN, aiming to inform patient-centered interventions. Study Design This article presents qualitative findings of a broader mixed-methods study published elsewhere. Semi-structured 1:1 interviews were conducted via Microsoft Teams with adults (≥18 years) who experienced a pregnancy within the past 5 years affected by severe HDFN (i.e., intrauterine transfusion, fetal loss after 14 weeks’ gestation, or neonatal death within 4 weeks of birth due to HDFN). A patient advocacy group ensured study design’s relevance, recruited participants, and helped interpret results. Interviews were audio-recorded, transcribed, and analyzed to identify key themes. Results Of 28 participants, 27 completed interviews. Participants reported a median 2 (range, 1–5) affected HDFN pregnancies and a median 4 (1–11) intrauterine transfusions during their most recent pregnancy affected by severe HDFN. Seven themes were identified: (1) diagnosis communication and information seeking, (2) emotional journey at diagnosis, (3) navigating the treatment regimen, (4) physical/emotional challenges during pregnancy, (5) impacts on social life, (6) experience at delivery, and (7) postdelivery adjustment and reflections. Results indicated that participants felt inadequately informed about their diagnosis, experienced significant emotional distress, along with difficulties managing intense monitoring/treatments. Many described their delivery as traumatic and their postpartum as very stressful, which influenced their decision about additional pregnancies. Conclusion These findings highlight opportunities to strengthen communication and support for pregnant individuals experiencing severe HDFN. Developing comprehensive support models and improving care, guided by patient preferences, could address the needs of affected individuals and families.
- 31 July 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 16 (03) , e171-e178
Open AccessUnderstanding Patient Perspectives and Experiences in Severe Hemolytic Disease of the Fetus and Newborn: Insights from Qualitative Interviews
Objective Maternal red cell alloimmunization is a rare pregnancy condition that can cause hemolytic disease of the fetus and newborn (HDFN), which can be serious and fatal. As subsequent alloimmunized pregnancies carry HDFN risk, families’ future pregnancy decisions may be affected. Findings from qualitative interviews in alloimmunized mothers are presented to understand experiences and perspectives during their previous pregnancy affected by severe HDFN, aiming to inform patient-centered interventions. Study Design This article presents qualitative findings of a broader mixed-methods study published elsewhere. Semi-structured 1:1 interviews were conducted via Microsoft Teams with adults (≥18 years) who experienced a pregnancy within the past 5 years affected by severe HDFN (i.e., intrauterine transfusion, fetal loss after 14 weeks’ gestation, or neonatal death within 4 weeks of birth due to HDFN). A patient advocacy group ensured study design’s relevance, recruited participants, and helped interpret results. Interviews were audio-recorded, transcribed, and analyzed to identify key themes. Results Of 28 participants, 27 completed interviews. Participants reported a median 2 (range, 1–5) affected HDFN pregnancies and a median 4 (1–11) intrauterine transfusions during their most recent pregnancy affected by severe HDFN. Seven themes were identified: (1) diagnosis communication and information seeking, (2) emotional journey at diagnosis, (3) navigating the treatment regimen, (4) physical/emotional challenges during pregnancy, (5) impacts on social life, (6) experience at delivery, and (7) postdelivery adjustment and reflections. Results indicated that participants felt inadequately informed about their diagnosis, experienced significant emotional distress, along with difficulties managing intense monitoring/treatments. Many described their delivery as traumatic and their postpartum as very stressful, which influenced their decision about additional pregnancies. Conclusion These findings highlight opportunities to strengthen communication and support for pregnant individuals experiencing severe HDFN. Developing comprehensive support models and improving care, guided by patient preferences, could address the needs of affected individuals and families.
- Open Access
- 7 March 2026
- Published by Wiley in Transfusion
- Vol. 66 (S1) , S5-S14
The THOR network best practices for females of childbearing potential with life‐threatening hemorrhage: Guidance for emergency medical services and hospitals
- 7 March 2026
- Published by Wiley in Transfusion
- Vol. 66 (S1) , S5-S14
Open AccessThe THOR network best practices for females of childbearing potential with life‐threatening hemorrhage: Guidance for emergency medical services and hospitals
- 16 February 2026
- Published by Wiley in Transfusion
- Vol. 66 (3) , 614-625
A critical moment: Standardizing red blood cell antibody reporting to reduce hemolytic disease of the fetus and newborn risk
- 16 February 2026
- Published by Wiley in Transfusion
- Vol. 66 (3) , 614-625
A critical moment: Standardizing red blood cell antibody reporting to reduce hemolytic disease of the fetus and newborn risk
- Open Access
- 8 July 2025
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 15 (03) , e146-e153
Alloimmunization in Pregnancy: Patient-reported Quality of Care, Mental Health Effects, and Impact Upon Daily Life
The purpose of this study was to investigate mental health and impacts upon daily life in patients with a history of pregnancy alloimmunization, and secondarily to examine the relationship between disease severity and quality of care on these outcomes.This was a survey administered between November 2022 and February 2023 to U.S. adults with a history of red cell alloimmunization in pregnancy. Mental health outcomes, quality of care, and daily life impacts were reported.The survey was completed by 127 alloimmunized adults. Anxiety (90.6%), guilt (74.8%), self-doubt (68.0%), isolation (71.4%), depression (68.3%), and symptoms of posttraumatic stress disorder (PTSD) (61.3%) were frequently reported. Mental health support was offered in 24.4%. Respondents reporting a high quality of care in their alloimmunized pregnancies (rating of 8/10 or higher) were significantly less likely than those who perceived receiving lower-quality care to report feelings of guilt (p = 0.0006), self-doubt (p = 0.04), depression (p = 0.03), and symptoms of PTSD (p = 0.001).Despite the pervasive patient burden, mental health support was infrequently offered, and patients reported low satisfaction with continuity of care and their providers' knowledge of alloimmunization. Clinicians interacting with alloimmunized patients must employ a comprehensive patient-centered approach to address the significant disease burden.
- 8 July 2025
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 15 (03) , e146-e153
Open AccessAlloimmunization in Pregnancy: Patient-reported Quality of Care, Mental Health Effects, and Impact Upon Daily Life
The purpose of this study was to investigate mental health and impacts upon daily life in patients with a history of pregnancy alloimmunization, and secondarily to examine the relationship between disease severity and quality of care on these outcomes.This was a survey administered between November 2022 and February 2023 to U.S. adults with a history of red cell alloimmunization in pregnancy. Mental health outcomes, quality of care, and daily life impacts were reported.The survey was completed by 127 alloimmunized adults. Anxiety (90.6%), guilt (74.8%), self-doubt (68.0%), isolation (71.4%), depression (68.3%), and symptoms of posttraumatic stress disorder (PTSD) (61.3%) were frequently reported. Mental health support was offered in 24.4%. Respondents reporting a high quality of care in their alloimmunized pregnancies (rating of 8/10 or higher) were significantly less likely than those who perceived receiving lower-quality care to report feelings of guilt (p = 0.0006), self-doubt (p = 0.04), depression (p = 0.03), and symptoms of PTSD (p = 0.001).Despite the pervasive patient burden, mental health support was infrequently offered, and patients reported low satisfaction with continuity of care and their providers' knowledge of alloimmunization. Clinicians interacting with alloimmunized patients must employ a comprehensive patient-centered approach to address the significant disease burden.
- Open Access
Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
Background/Objectives: Pregnancies complicated by red cell alloimmunization can progress to hemolytic disease of the fetus and newborn (HDFN), requiring close monitoring and timely intervention to prevent fetal/neonatal morbidity and mortality. This study investigated disease presentation, interventions, and outcomes in respondents with a history of alloimmunized pregnancy. Methods: This was a retrospective cross-sectional survey study administered online to alloimmunized patients between November 2022–February 2023. A total of 127 participants reported on 200 alloimmunized pregnancies. Distribution of pregnancy characteristics, antibodies and titers, monitoring, treatments and fetal outcomes were described and stratified where appropriate by fetal antigen status and disease severity. Outcomes and management practices in subsequent pregnancies following fetal loss to HDFN are reported. Results: Multiple antibodies were present in 42% of pregnancies with known antibody type (80/192). Titers reached critical levels (any titer for Anti-K; ≥16 for all other antibodies) in 71% (125/176) of pregnancies where titer was reported. Among fetal antigen positive pregnancies with critical titers, intrauterine transfusions were conducted in 40% (42/106), intravenous immunoglobulin was administered in 14% (15/106), plasmapheresis in 7% (7/106), and phenobarbital in 9% (9/106). Complications from transfusion were reported in 38% of pregnancies receiving intrauterine transfusion (17/45). Fetal death due to HDFN or complications from intrauterine transfusion was reported in 9% of antigen positive pregnancies with critical titers (10/106) and 16% of pregnancies receiving intrauterine transfusion (7/45). Conclusions: Disease presentation and severity complements previous research in this disease population, however, monitoring practices were diverse. Fetal death and intrauterine complication rates were higher than those previously reported in large international referral centers. Development of best practices and centralized referral centers may improve disease outcomes.
Open AccessPatient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
Background/Objectives: Pregnancies complicated by red cell alloimmunization can progress to hemolytic disease of the fetus and newborn (HDFN), requiring close monitoring and timely intervention to prevent fetal/neonatal morbidity and mortality. This study investigated disease presentation, interventions, and outcomes in respondents with a history of alloimmunized pregnancy. Methods: This was a retrospective cross-sectional survey study administered online to alloimmunized patients between November 2022–February 2023. A total of 127 participants reported on 200 alloimmunized pregnancies. Distribution of pregnancy characteristics, antibodies and titers, monitoring, treatments and fetal outcomes were described and stratified where appropriate by fetal antigen status and disease severity. Outcomes and management practices in subsequent pregnancies following fetal loss to HDFN are reported. Results: Multiple antibodies were present in 42% of pregnancies with known antibody type (80/192). Titers reached critical levels (any titer for Anti-K; ≥16 for all other antibodies) in 71% (125/176) of pregnancies where titer was reported. Among fetal antigen positive pregnancies with critical titers, intrauterine transfusions were conducted in 40% (42/106), intravenous immunoglobulin was administered in 14% (15/106), plasmapheresis in 7% (7/106), and phenobarbital in 9% (9/106). Complications from transfusion were reported in 38% of pregnancies receiving intrauterine transfusion (17/45). Fetal death due to HDFN or complications from intrauterine transfusion was reported in 9% of antigen positive pregnancies with critical titers (10/106) and 16% of pregnancies receiving intrauterine transfusion (7/45). Conclusions: Disease presentation and severity complements previous research in this disease population, however, monitoring practices were diverse. Fetal death and intrauterine complication rates were higher than those previously reported in large international referral centers. Development of best practices and centralized referral centers may improve disease outcomes.
- Open Access
- 23 July 2024
- Published by Wiley in Transfusion
- Vol. 64 (9) , 1784-1790
A review of attitudes to urgent RhD‐positive transfusions in female patients and the risk for hemolytic disease of the fetus and newborn
- 23 July 2024
- Published by Wiley in Transfusion
- Vol. 64 (9) , 1784-1790
Open AccessA review of attitudes to urgent RhD‐positive transfusions in female patients and the risk for hemolytic disease of the fetus and newborn
- 2 April 2024
- Published by Wiley in Transfusion
- Vol. 64 (S2) , S100-S110
Receipt of RhD‐positive whole blood for life‐threatening bleeding in female children: A survey in alloimmunized mothers regarding minimum acceptable survival benefit relative to risk of maternal alloimmunization to anti‐D
Background: Low‐titer group O whole blood (LTOWB) for treatment of hemorrhagic shock sometimes necessitates transfusion of RhD‐positive units due to short supply of RhD‐negative LTOWB. Practitioners must choose between using RhD‐positive LTOWB when RhD‐negative is unavailable against the risk to a female of childbearing potential of becoming RhD‐alloimmunized, risking hemolytic disease of the fetus and newborn (HDFN) in future children, or using component therapy with RhD‐negative red cells. This survey asked females with a history of red blood cell (RBC) alloimmunization about their risk tolerance of RhD alloimmunization compared to the potential for improved survival following transfusion of RhD‐positive blood for an injured RhD negative female child.Study Design and Methods: A survey was administered to RBC alloimmunized mothers. Respondents were eligible if they were living in the United States with at least one red cell antibody known to cause HDFN and if they had at least one RBC alloimmunized pregnancy.Results: Responses from 107 RBC alloimmmunized females were analyzed. There were 32/107 (30%) with a history of severe HDFN; 12/107 (11%) had a history of fetal or neonatal loss due to HDFN. The median (interquartile range) absolute improvement in survival at which the respondents would accept RhD‐positive transfusions for a female child was 4% (1%–14%). This was not different between females with and without a history of severe or fatal HDFN (p = .08 and 0.38, respectively).Conclusion: Alloimmunized mothers would accept the risk of D‐alloimmunization in a RhD‐negative female child for improved survival in cases of life‐threatening bleeding.
- 2 April 2024
- Published by Wiley in Transfusion
- Vol. 64 (S2) , S100-S110
Receipt of RhD‐positive whole blood for life‐threatening bleeding in female children: A survey in alloimmunized mothers regarding minimum acceptable survival benefit relative to risk of maternal alloimmunization to anti‐D
Background: Low‐titer group O whole blood (LTOWB) for treatment of hemorrhagic shock sometimes necessitates transfusion of RhD‐positive units due to short supply of RhD‐negative LTOWB. Practitioners must choose between using RhD‐positive LTOWB when RhD‐negative is unavailable against the risk to a female of childbearing potential of becoming RhD‐alloimmunized, risking hemolytic disease of the fetus and newborn (HDFN) in future children, or using component therapy with RhD‐negative red cells. This survey asked females with a history of red blood cell (RBC) alloimmunization about their risk tolerance of RhD alloimmunization compared to the potential for improved survival following transfusion of RhD‐positive blood for an injured RhD negative female child.Study Design and Methods: A survey was administered to RBC alloimmunized mothers. Respondents were eligible if they were living in the United States with at least one red cell antibody known to cause HDFN and if they had at least one RBC alloimmunized pregnancy.Results: Responses from 107 RBC alloimmmunized females were analyzed. There were 32/107 (30%) with a history of severe HDFN; 12/107 (11%) had a history of fetal or neonatal loss due to HDFN. The median (interquartile range) absolute improvement in survival at which the respondents would accept RhD‐positive transfusions for a female child was 4% (1%–14%). This was not different between females with and without a history of severe or fatal HDFN (p = .08 and 0.38, respectively).Conclusion: Alloimmunized mothers would accept the risk of D‐alloimmunization in a RhD‐negative female child for improved survival in cases of life‐threatening bleeding.